Patents by Inventor Manuel A. Navia

Manuel A. Navia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030181470
    Abstract: The invention is based on the discovery of a new class of heterocyclic compounds having, for example, antibacterial properties. The D-Ala-D-Ala ligase enzyme is a critical pathway enzyme in the bacterial cell-wall synthesis. The compounds can bind to and inhibit the enzyme D-Ala-D-Ala ligase. The new compounds' activity combined with their ability to cross bacterial cell membranes makes them suitable for use as antibacterial drugs or other antibacterial applications.
    Type: Application
    Filed: June 28, 2002
    Publication date: September 25, 2003
    Inventors: Paul J. Ala, Janid A. Ali, Jacob J. Clement, Patrick R. Connelly, Carlos H. Faerman, Christopher Farady, John V. Gazzaniga, Andrew S. Magee, Salvatore A. Marchese, Scott T. Moe, Manuel A. Navia, Emanuele Perola, Paul Will
  • Publication number: 20030176436
    Abstract: This invention relates to novel heterocyclic compounds and to their use in the medical treatment or prophylaxis of bacterial infections, or their use as antiseptics, sterilizants, or disinfectants.
    Type: Application
    Filed: June 28, 2002
    Publication date: September 18, 2003
    Inventors: Paul J. Ala, Janid A. Ali, Jacob J. Clement, Carlos H. Faerman, John V. Gazzaniga, Andrew S. Magee, Salvatore A. Marchese, Scott T. Moe, Manuel A. Navia, Emanuele Perola, Paul Will
  • Publication number: 20030166645
    Abstract: The invention relates to nitrofuran-containing compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making the compounds, and methods for identifying compounds with desired biological activity.
    Type: Application
    Filed: June 25, 2002
    Publication date: September 4, 2003
    Inventors: Paul J. Ala, Jacob J. Clement, Andrew S. Magee, Scott T. Moe, Manuel A. Navia, Aloka Roy
  • Publication number: 20030119061
    Abstract: The invention is based on the discovery that certain small molecules can bind to the ATP binding site of D-Ala-D-Ala ligase, even in the absence of the enzyme's substrate, and can cause a conformational change in the enzyme structure similar to that which occurs upon binding of ATP and substrate to the enzyme. Without wishing to be bound by any theory, it is believed that such a conformational change is required for either activation or inhibition of the enzyme. The information obtained from this discovery has enabled identification of key interactions in the active site of the enzyme, as well as the design and opimization of inhibitors.
    Type: Application
    Filed: June 28, 2002
    Publication date: June 26, 2003
    Inventors: Paul J. Ala, Janid A. Ali, Carlos H. Faerman, James P. Griffith, Andrew S. Magee, Scott T. Moe, Manuel A. Navia, Emanuele Perola, Patrick R. Connelly
  • Patent number: 6011001
    Abstract: A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. A preferred protein is an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease. Crosslinked enzyme crystals preferably retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred enzyme:Pronase.TM. ratio is 40:1. Enzyme crystals that are crosslinked may be microcrystals having a cross-section of 10.sup.-1 mm or less.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 4, 2000
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Manuel A. Navia, Nancy L. St. Clair
  • Patent number: 6004768
    Abstract: Proteins such as enzymes and antibodies are immobilized by crosslinking crystals of the proteins such as microcrystals having a cross-section of 10.sup.-1 mm or less with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. Crystals of an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease may be crosslinked to provide crosslinked enzyme crystals that retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred Pronase.TM.:enzyme ratio is 1:40.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 21, 1999
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Manuel A. Navia, Nancy L. St. Clair
  • Patent number: 5976529
    Abstract: A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. A preferred protein is an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease. Crosslinked enzyme crystals preferably retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred enzyme:Pronase.TM. ratio is 1:40. Enzyme crystals that are crosslinked may be microcrystals having a cross-section of 10.sup.-1 mm or less.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 2, 1999
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Manuel A. Navia, Nancy L. St. Clair
  • Patent number: 5849296
    Abstract: A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. A preferred protein is an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease. Crosslinked enzyme crystals preferably retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred enzyme:Pronase.TM. ratio is 1:40. Enzyme crystals that are crosslinked may be microcrystals having a cross-section of 10.sup.-1 mm or less.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 15, 1998
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Manuel A. Navia, Nancy L. St. Clair
  • Patent number: 5801022
    Abstract: A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent such as glutaraldehyde, and if desired lyophilizing the crosslinked crystals for storage. Crosslinking of the protein crystals provides stabilization for use under harsh conditions and for lyophilizing. The crystals crosslinked may be microcrystals having a cross-section of 10.sub.-1 mm or less. Crosslinked thermolysin, esterase, elastase, asparaginase and lysozyme crystals and crosslinked crystals of lipase from Geotrichum candidum and Candida cylindracea and of porcine origin can be used to convert a substrate to a product. Crosslinked thermolysin crystals are prepared that retain at least 96% of their initial activity after incubation for 4 days in the presence of a concentration of Pronase.TM. such as a thermolysin:Pronase.TM.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 1, 1998
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Manuel A. Navia, Nancy L. St. Clair
  • Patent number: 5618710
    Abstract: A protein such as an enzyme of antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. A preferred protein is an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease. Crosslinked enzyme crystals preferably retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred enzyme:Pronase.TM. ratio is 1:40. Enzyme crystals that are crosslinked may be microcrystals having a cross-section of 10.sup.-1 mm or less.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: April 8, 1997
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Manuel A. Navia, Nancy L. St. Clair